CLOSE

Specials

  • Other
  • Healthcare Consulting
  • Revenue Cycle Management

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
healthcarebusinessreview

About us

Solutions/Services Providers

  • Home
  • News
  • Contributors
  • Magazine
  • Conferences
  • Newsletter

Nominate a Company

Our subscribers nominate the companies with whom they have collaborated and gotten results. If you think there is a company that deserves to be on our upcoming prestigious annual list of Top HealthcareBuisness companies, please write to us about them and the reasons you think they need to be on the list

* 

Thank You!

checkmark

Your nomination request for upcoming annual list of "Top HealthcareBuisness Companies" has been Successfully Sent . We will be in touch with you shortly.

Data not inserted

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

How Pioneering Technologies Streamline and...

Andrew Parker, Vice President, Corporate Business...

3D Printed Talus Replacement

Jisun J. Lee, MS, DPM, Mica Murdoch, DPM, Ashley...

Connected Care

Samuel Alfano DO, Medical Director, Clinical...

The [EHR] Doctor is in

Rebecca G. Mishuris, MD, MPH, MS, Chief Medical...

Hospitals Rely on New Technologies to...

Andrew Parker, Vice President-Human Resources &...

Medical Spine Care: Have We Finally Arrived?

Michael Geraci, Medical Director Comprehensive Spine...

The Modern Day Biomechanics

Julio Martinez, Medical Director, Baystate Health

Reducing Clinical Variation in Medicine...

Michael C. Sanders, M.D., Chief Medical Informatics...

How Pioneering Technologies Streamline and...

Andrew Parker, Vice President, Corporate Business...

3D Printed Talus Replacement

Jisun J. Lee, MS, DPM, Mica Murdoch, DPM, Ashley...

Connected Care

Samuel Alfano DO, Medical Director, Clinical...

The [EHR] Doctor is in

Rebecca G. Mishuris, MD, MPH, MS, Chief Medical...

Hospitals Rely on New Technologies to...

Andrew Parker, Vice President-Human Resources &...

Medical Spine Care: Have We Finally Arrived?

Michael Geraci, Medical Director Comprehensive Spine...

The Modern Day Biomechanics

Julio Martinez, Medical Director, Baystate Health

Reducing Clinical Variation in Medicine...

Michael C. Sanders, M.D., Chief Medical Informatics...

The Rise of Genetics and Precision Medicine in Cardiology

By Bani M. Azari, MD, PhD, Medical Director, Program for Cardiac genetics, Genomics and Precision Medicine at Northwell Health and Assistant Professor, Department of Cardiology, North Shore University Hospital
Tweet

The promise of the human genome project was to create a means to understand human disease and target specific therapies, yet 20 years later, we are only just starting to see the glimmer of that promise being delivered.


Cardiac genetic testing for dilated cardiomyopathy, despite having a class 1 indication,


continues to be a widely underutilized tool. Many factors contribute to it underutilization, including the access to and costs of genetic testing; nevertheless, the largest barrier continues to remain the ordering physician’s opinion of “will this result in the change of management for this patient.”


Previously, genetic testing in cardiomyopathy only had the power to provide a definitive diagnosis and assist with an understanding of disease progression. It primarily served to identify family members at risk.


However, this is rapidly changing. Approval of therapeutics targeted to patients with a genetic cause for their cardiomyopathy is under development, in clinical trials, and the case of the transthyretin (TTR)cardiac amyloidosis, part of the new standard of care.


Here we outline the rapid changes seen in clinical practice following the introduction of precision medicine therapeutics for TTR amyloidosis and what to look forward to in the next few years.


Cardiac amyloidosis has been traditionally thought of as a rare disease with three distinct etiologies: AL amyloid, wild type (senile) TTR amyloidosis, and mutant or hereditary TTR cardiac amyloidosis. Up until five years ago, cardiac amyloid workup would include determining if the patient had AL amyloidosis and offering chemotherapy or TTR amyloidosis, adjusting heart failure therapy, and offering palliative care. Cardiac imaging for TTR cardiac amyloidosis was limited to academic medical centers, and genetic testing, while available, was rarely performed for family screening.


In the summer of 2018, the results of phase 3 clinical trials for patisiran and inotersen were published simultaneously in the NEJM, demonstrating the use of silencing RNAi and antisense oligonucleotide therapeutics to inhibit hepatic expression of mutant TTR. These two drugs were the first approved targeted therapies to silence mutant gene expression and the first wide application of targeted therapy in cardiomyopathy.



"One of the more promising therapeutics on the horizon is ARRY-797. Currently, in phase 3 clinical trials, this drug inhibits the downstream over activation of the p38 mitogen-activated protein kinase (MAPK) that occurs in the presence of a non-functional lamin A (LMNA) protein"



Now the outcome of a genetic test has a direct impact on therapeutic choice in TTR amyloidosis. The collapse of this barrier is a dramatic increase in the utilization of genetic testing for cardiac amyloidosis. In our system, patients referred for genetic evaluation of amyloidosis rose to 30% of all patients referred for cardiac genetic testing.


Precision medicine for cardiomyopathy is not limited to amyloidosis. Multiple targeted therapeutics for cardiovascular diseases is currently being developed or are in clinical trials.


One of the more promising therapeutics on the horizon is ARRY-797. Currently, in phase 3 clinical trials, this drug inhibits the downstream over activation of the p38 mitogen-activated protein kinase (MAPK) that occurs in the presence of a non-functional lamin A (LMNA) protein. The unchecked activation of the p38 MAPK pathway causes downstream changes in the cardiomyocytes and cardiac conduction tissue, leading to a trial fibrillation, ventricular tachycardia, and dilated cardiomyopathy. LMNA mutations are one of the most common, severe, and highly penetrant causes of dilated cardiomyopathy and sudden cardiac death.


While it remains to be seen if this drug will significantly halt disease progression, targeted therapies based on cardiomyopathies are on the rise.


As physicians and scientists continue to identify the mechanisms behind the development of cardiomyopathy and target these pathways directly, eventually deliver the promise of precision medicine in cardiomyopathy. The next few years promise to be an exciting time for precision medicine in cardiology and beyond. This is just the beginning.


 


Weekly Brief

loading
> <
  • Other 2021

    Top Vendors

    Current Issue
  • Other 2020

    Top Vendors

    Current Issue

Read Also

Technology in Healthcare should be Proactive, ahead of Risks and Aiding Focus on Variations to Plan

Roni H. Amiel, Co-Founder & CTO, Pinscriptive
Technology in Healthcare should be Proactive, ahead of Risks and Aiding Focus on Variations to Plan

How Pioneering Technologies Streamline and Improve Clinical Care

Andrew Parker, Vice President, Corporate Business Development and General Counsel, bioMérieux, Inc. [EPA:BIM]
How Pioneering Technologies Streamline and Improve Clinical Care

3D Printed Talus Replacement

Jisun J. Lee, MS, DPM, Mica Murdoch, DPM, Ashley McClain, DPM, Broadlawns Medical Center
3D Printed Talus Replacement

Connected Care

Samuel Alfano DO, Medical Director, Clinical Informatics, Crozer Chester Medical Center
Connected Care
The [EHR] Doctor is in

The [EHR] Doctor is in

Rebecca G. Mishuris, MD, MPH, MS, Chief Medical Information Officer, Boston Medical Center & Assistant Professor, Boston University School of Medicine
Hospitals Rely on New Technologies to Strengthen Patient Care

Hospitals Rely on New Technologies to Strengthen Patient Care

Andrew Parker, Vice President-Human Resources & General Counsel - Americas, bioMérieux, Inc. [EPA:BIM]

Medical Spine Care: Have We Finally Arrived?

Michael Geraci, Medical Director Comprehensive Spine Program, Catholic Health
Medical Spine Care: Have We Finally Arrived?

The Modern Day Biomechanics

Julio Martinez, Medical Director, Baystate Health
The Modern Day Biomechanics
Loading...

Copyright © 2021 Healthcare Business Review . All rights reserved. |  Subscribe follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.healthcarebusinessreview.com/cxoinsight/the-rise-of-genetics-and-precision-medicine-in-cardiology-nwid-101.html